Compare CANF & FCUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CANF | FCUV |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 5.9M |
| IPO Year | 2011 | 2013 |
| Metric | CANF | FCUV |
|---|---|---|
| Price | $3.55 | $4.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9,750.00 | N/A |
| AVG Volume (30 Days) | ★ 668.0K | 17.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $398,137.00 |
| Revenue This Year | $461.72 | N/A |
| Revenue Next Year | $290,391.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.17 | $0.50 |
| 52 Week High | $10.40 | $12.83 |
| Indicator | CANF | FCUV |
|---|---|---|
| Relative Strength Index (RSI) | 39.99 | 49.77 |
| Support Level | $0.60 | $3.32 |
| Resistance Level | $4.74 | $5.25 |
| Average True Range (ATR) | 0.70 | 0.53 |
| MACD | -0.20 | -0.23 |
| Stochastic Oscillator | 0.44 | 21.56 |
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
Focus Universal Inc offers smart devices, IoT products, and patented products and technologies for 5G telecommunications and network security. It is focused on commercializing its universal smart technology and financial reporting software. Its product line includes various digital, analog, and quantum light meters and filtration products, the Ubiquitor universal smart device, SEC Financial Reporting Software, and other smart devices and sensors. The company's reportable segments are Corporate and IoT, which derives maximum revenue, and Perfecular and Lusher. The Corporate and IoT segment includes its LED and IoT installation and management business (under Smart AVX), specializing in LED and display systems, home theaters, lighting control, automation, and integration.